Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications
A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy
Published: April 08, 2019
Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes.
Journal: Drugs of today (Barcelona, Spain : 1998)
Published: December 20, 2014
Showing 1-2 of 2
Last Updated: 09/26/2026